There has been a lot of press around the recent announcement that Senator Kennedy has brain cancer. The papers I have read and news reports have been good (very surprisingly) about not making any predictions pertaining to his future. Of course, there have been veiled allusions about what the cost of his death would mean [...]
NCI’s Office of Advocacy Relations (OAR) will host its third teleconference, Understanding the Role of NCI’s Clinical Trials Advisory Committee, on Wednesday, May 21, from 2:00 – 3:00 p.m., EST. The featured speakers are: Dr. Sheila Prindiville, Director, Coordinating Center for Clinical Trials, NCI’s Office of the Director; Ms. Susan Leigh, Advocate Member, CTAC; Col. [...]
My wife told the Dev today what school he'll be going to in the fall. I wanted to be around for that conversation, but I was glad she initiated it. Luckily I'm the only person who knows how to get on the new computer, so I was able to show Dev the website for his [...]
Increasingly, we are finding pressure from the insurance world to demonstrate that the treatments we go through are the best available, meaning the most cost effective and yielding the best results. Research into prostate cancer is lagging and has not relied on evidence based results. Treatment decisions are often made on nonscientific consensus of the [...]
The FDA has announced its conditional approval, pending minor changes to the protocol, for a clinical trial for the treatment of recurrent prostate cancer with the Sonablate(R) 500 (HIFU) in men who have failed external beam radiation therapy. Dr. Herbert Lepor, Chairman of Urology at NYU School of Medicine will serve as the medical monitor [...]